Novartis expects new drugs to boost sales by at least 4% until 2026
Reuters
Published Dec 02, 2021 06:29
Updated Dec 02, 2021 07:06
ZURICH (Reuters) -Novartis is confident of delivering annual revenue growth of 4% or higher until 2026, as it banks on multi-billion dollar sales of experimental and approved drugs including arthritis and psoriasis medicine Cosentyx.
Sales from these new products is expected to exceed and make up for a $9 billion hit from launches of copycat versions of its products in this period, the Swiss drugmaker on Thursday said in a presentation https://www.novartis.com/sites/novartis_com/files/novartis-r-d-day-2021.pdf ahead of an investor briefing.
The update comes weeks after Novartis said it would sell its stake in Roche to simplify its structure and focus on key offerings against diseases such as arthritis and cancer, following the launch of a review of its generic-drug unit Sandoz.
Novartis also expects core margins in innovative medicines to reach the high 30s by 2026, adding it had up to 20 assets in its pipeline that had blockbuster potential - meaning they could eventually yield annual sales of at least $1 billion.
The company said it was committed to maintain a strong and growing dividend in Swiss francs.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.